ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1459

Racial Comparisons of Children with Idiopathic Uveitis: Results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

Sheila T. Angeles-Han1,2,3, Curtis Travers3, Mindy S. Lo4, C. Egla Rabinovich5, Sampath Prahalad6 and and CARRA Registry Investigators, 1Children's Healthcare of Atlanta, Atlanta, GA, 2Ophthalmology, Emory University School of Medicine, Atlanta, GA, 3Pediatrics, Emory University School of Medicine, Atlanta, GA, 4Medicine/Immunology, Children's Hospital Boston, Boston, MA, 5Duke University Medical Center, Durham, NC, 6Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Pediatric rheumatology, race/ethnicity and uveitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Childhood uveitis can lead to poor
visual outcomes. Our data from single center studies suggests that non-Hispanic
African American children (NHB) with non-inflammatory uveitis have increased ocular
complications, and that African American race is a predictor of vision loss and
blindness.  Our aim is to characterize the epidemiology and clinical course of
non-Hispanic White (NHW) and NHB children with idiopathic uveitis in the CARRA
Registry.

Methods: There were 65 NHW and 11 NHB children
with idiopathic uveitis enrolled in the CARRA Registry.  Demographic and uveitis-related
data were collected from time of diagnosis to enrollment.   We compared
clinical characteristics of NHB and NHW children using 2 sample t-tests and chi-square
tests. Logistic regression was used to model risk factors for vision loss.

Results: The 11 (14.5%) NHB children had a mean
age of uveitis onset of 8.4 ± 3.0 years, 6 (55%) were female, and 3 (30%) were ANA
positive (Table 1).  Uveitis was primarily anterior in location (73%) and bilateral
(82%). Ocular complications were common (64%): cataracts (36%), increased
intraocular pressure (27%), posterior synechiae (27%) and keratic precipitates
(27%).  Uncorrected abnormal or blind vision was reported in the right eye in
86%, and in 71% in the left eye. 

Comparing NHW and NHB children (Table 1),
there were no significant differences in gender, smoking exposure, ANA
positivity, age of uveitis onset, location of uveitis, laterality, or presence
and type of ocular complications.  There were also no differences in insurance
status, age at first rheumatology visit, or time to first rheumatology visit
from disease onset. Medication use was similar except for increased use of oral
methotrexate in NHW (p=0.003).   There was a trend towards increased vision
loss or blindness in NHB children overall, but this was only statistically
significant in the right eye for uncorrected vision (85.7% vs. 36.4%, p =
0.034).  This may be secondary to our sample size or to one eye being most
affected. On logistic regression analysis, NHB race was a significant predictor
of vision loss in the right eye (OR = 10.5, (95% CI 1.16-95.11).  This was not
significant in the left eye (OR = 3.61, (95% CI 0.63 – 20.71).

Conclusion: In the CARRA registry, 14% of children
with idiopathic uveitis were NHB.  The odds of developing vision loss were 10.5
times greater in NHB children compared to NHW.  Although the numbers of NHB
children in this registry are small, these results support our previous
findings of racial
differences in the visual outcomes of children with uveitis. 
This highlights the need for further exploration of the impact of race in a
racially diverse cohort.

Table 1.
Comparison of Non-Hispanic White and Black Children with Idiopathic Uveitis

 

Characteristics

N = 76 unless otherwise specified

N (%) unless otherwise specified

Overall

N = 76

Non-Hispanic whites

N = 65

Non-Hispanic Blacks

N = 11

p-value

Demographics

 

 

 

 

Age at baseline visit,

mean ± sd

11.9 ± 3.7

11.9 ± 3.8

11.8 ± 3.7

0.929

Female

39 (51.3%)

33 (50.8%)

6 (54.6%)

1.00

Insured (N = 75)

74 (98.7%)

63 (98.4%)

11 (100.0%)

1.00

Smoker (N = 61)

3 (4.9%)

3 (5.5%)

0 (0.0%)

1.00

Smoking in Household (N = 38)

7 (18.4%)

5 (15.2%)

2 (40.0%)

0.223

Disease Characteristics

 

 

 

 

Age at onset (years) (N = 74), mean ± sd

8.5 ± 3.6

8.5 ± 3.7

8.4 ± 3.0

0.900

Duration of uveitis (years)

(N = 74), mean ± sd

3.5 ± 2.6

3.6 ± 2.7

2.8 ± 2.5

0.367

Age at 1st rheum visit (years)

(N = 74), mean ± sd

9.2 ± 3.5

9.2 ± 3.6

9.1 ± 2.7

0.929

Time to 1st rheum visit (years)

(N = 74), mean ± sd

0.7 ± 1.0

0.7 ± 1.1

0.7 ± 0.5

0.892

ANA, Positive (N = 61)

25 (41.0%)

22 (43.1%)

3 (30.0%)

0.505

Location

 

 

 

 

Anterior

49 (64.5%)

41 (63.1%)

8 (72.7%)

0.936

Intermediate

11 (14.5%)

10 (15.4%)

1 (9.1%)

Posterior

3 (3.9%)

3 (4.6%)

0 (0.0%)

Panuveitis

13 (17.1%)

11 (16.9%)

2 (18.2%)

     Bilateral involvement

56 (73.7%)

47 (72.3%)

9 (81.8%)

0.717

Length of Current Episode

 

 

 

 

In Remission

36 (47.4%)

32 (49.2%)

4 (36.4%)

0.244

< 3 months

9 (11.8%)

6 (9.2%)

3 (27.3%)

> 3 months

31 (40.8%)

27 (41.5%)

4 (36.4%)

Right Eye Uncorrected, Abnormal/Blind, (N = 51)

22 (43.1%)

16 (36.4%)

6 (85.7%)

0.034*

Right Eye Corrected, Abnormal/Blind, (N = 41)

7 (17.1%)

5 (13.9%)

2 (40.0%)

0.196

Left Eye Uncorrected, Abnormal/Blind, (N = 51)

23 (45.1%)

18 (40.9%)

5 (71.4%)

0.222

Left Eye Corrected, Abnormal/Blind, (N = 42)

6 (14.3%)

5 (13.5%)

1 (20.0%)

1.00

Ocular Complications

57 (75%)

50 (76.9%)

7 (63.6%)

0.496

Increased Intraocular Pressure

27 (35.5%)

24 (36.9%)

3 (27.3%)

0.737

Cataracts

25 (32.9%)

21 (32.3%)

4 (36.4%)

1.00

Posterior Synechiae

18 (23.7%)

15 (23.1%)

3 (27.3%)

1.00

Band Keratopathy

14 (18.4%)

12 (18.5%)

2 (18.2%)

1.00

Macular Edema

13 (17.1%)

13 (20.0%)

0 (0.0%)

0.194

Keratic Precipitates

11 (14.5%)

8 (12.3%)

3 (27.3%)

0.349

Medication Use, Ever

 

 

 

 

Topical Steroid Drops (N = 72)

68 (94.4%)

59 (95.2%)

9 (90.0%)

1.00

Methotrexate Oral (N = 65)

38 (58.4%)

37 (66.1%)

1 (11.1%)

0.003*

Methotrexate Subcutaneous (N = 65)

41 (63.1%)

33 (58.9%)

8 (88.9%)

0.137

Biologics (N = 76)

40 (52.6%)

34 (52.3%)

6 (54.6%)

1.00

     Infliximab (N = 40)

25 (62.5%)

22 (64.7%)

3 (50.0%)

0.654

     Adalimumab (N = 40)

18 (45.0%)

15 (44.2%)

3 (50.0%)

1.00

*p <0.05

 

 

 

 


Disclosure: S. T. Angeles-Han, NIH NEI K23-EY021760, 2; C. Travers, None; M. S. Lo, None; C. E. Rabinovich, Abbie Vie, 2,UCB Pharma, 2,Hoffmann-La Roche Inc., 2,Janssen Research & Development, LLC, 2; S. Prahalad, Novartis, 9.

To cite this abstract in AMA style:

Angeles-Han ST, Travers C, Lo MS, Rabinovich CE, Prahalad S. Racial Comparisons of Children with Idiopathic Uveitis: Results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/racial-comparisons-of-children-with-idiopathic-uveitis-results-from-the-childhood-arthritis-and-rheumatology-research-alliance-carra-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/racial-comparisons-of-children-with-idiopathic-uveitis-results-from-the-childhood-arthritis-and-rheumatology-research-alliance-carra-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology